^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)

i
Associations
Company:
Guangzhou Trinomab Biotechnology
Drug class:
Dendritic cell activator
Associations
Phase 1
Guangdong 999 Brain Hospital
Completed
Last update posted :
05/27/2022
Initiation :
03/01/2016
Primary completion :
10/31/2017
Completion :
06/30/2019
CD4
|
tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)
Phase 1
Guangdong 999 Brain Hospital
Completed
Last update posted :
05/27/2022
Initiation :
03/01/2016
Primary completion :
10/31/2017
Completion :
06/30/2019
CD4
|
tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)
Phase 1
Guangdong 999 Brain Hospital
Completed
Last update posted :
05/27/2022
Initiation :
03/01/2016
Primary completion :
10/31/2017
Completion :
06/30/2019
CD4
|
tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)